Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...
Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch
SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System ...
It’s here: Dexcom is kicking off the international rollout of the newest generation of its real-time continuous glucose monitor, the G7, to help adults and children with diabetes digitally track their ...
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that Health Canada ...
EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today it has secured CE ...
DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to invest in for the next 2 years. On April 30, DexCom reported Q1 ...
It takes two: After making its commercial debut early this year, Dexcom’s latest continuous glucose monitor is wrapping up 2023 by connecting with its first automated insulin pump partner, courtesy of ...
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of ...
Dexcom is working closely with its insulin pump partners to ensure that Dexcom G7 15 Day will be compatible with automated insulin delivery systems upon launch. Dexcom G7 15 Day is expected to launch ...
Hosted on MSN
DexCom reports strong Q1 as OTC CGMs reach new users
DexCom posted better-than-expected Q1 2026 results, with revenue up 15% year-over-year on strong uptake of its G7 continuous glucose monitor and expanded coverage for type 2 diabetes patients not ...
After months of international availability, the Dexcom G7 constant glucose monitor received its FDA clearance to distribute in the US. Ahead of the wide rollout, we got to go hands-on with a demo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results